Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

BACKGROUND: HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15–30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Oncol
Päätekijät: Lesurf, R., Griffith, O. L., Griffith, M., Hundal, J., Trani, L., Watson, M. A., Aft, R., Ellis, M. J., Ota, D., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Boughey, J. C., Unzeitig, G., Buzdar, A. U., Hunt, K. K., Mardis, E. R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5790063/
https://ncbi.nlm.nih.gov/pubmed/28453704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx048
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia